Daiichi Sankyo Moves Forward On Antibody Drug For Multiple Cancers
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is pressing forward with its simultaneous trials of four different antibody drugs to treat several types of cancers